STAT

NOVEMBER 20, 2023

In the depths of the Covid-19 pandemic, something strange happened: For a year or two, illnesses that used to emerge like clockwork when fall and winter arrived — flu, RSV, and the myriad viruses that cause colds — did not sicken us. The cause now appears clear: The measures we took to avoid the new disease, including isolating and social distancing, muscled most other respiratory pathogens out of the cold-and-flu-season picture.

357

357

PharmaVoice

NOVEMBER 20, 2023

Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

280

280

STAT

NOVEMBER 20, 2023

Cell and gene therapies are the next frontier in medicine and promise long-sought hope for people living with incurable and fatal conditions. As their promise increasingly becomes reality, the FDA’s gatekeeping role is important. To truly serve the people who need these medications, the FDA must be a good-faith partner and deploy the tools my fellow congressional lawmakers and I helped secure.

329

329

Pharma Times

NOVEMBER 20, 2023

The centre will help discover new treatments to prevent, halt and cure the condition - News - PharmaTimes

134

134

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

NOVEMBER 20, 2023

Hospitals’ list prices for surgeries, therapies, and other procedures always come with massive discounts. Financial documents at a prominent hospital system in Los Angeles show just how large those discounts are — and how raw of a deal uninsured patients could be getting. Cedars-Sinai reported more than $10.2 billion of gross patient revenue in the most recent three-month period that ended Sept. 30, according to new financial documents.

Hospitals 312

Hospitals Documentation 312

The Guardian - Pharmaceutical Industry

NOVEMBER 20, 2023

People should not die because of their income or where they were born. We must have the courage to stand up to the pharmaceutical industry Here is a simple moral proposition. No one in America, or anywhere in the world, should die or suffer unnecessarily because they cannot afford a prescription drug which, in many cases, costs a few cents or a few dollars to manufacture.

111

111

Digital Pharmacist

NOVEMBER 20, 2023

The holiday season is upon us, and with this time of year comes an influx of pharmacy calls. As patients seek medication refills before they travel and inquire about vaccinations before their holiday gatherings, it’s crucial for pharmacies to optimize their Interactive Voice Response (IVR) systems. A well-thought-out IVR menu and efficient call routing can significantly enhance the customer experience and streamline operations during the busy holiday period.

Health and Personal Care Stores 105

Health and Personal Care Stores Vaccines Communication Pharmacy Management 105

STAT

NOVEMBER 20, 2023

Health systems whose budgets were squeezed dry during the pandemic are creeping back into the black, but they’re far from the days when they had cash to blow on flashy tech pilots that might never pan out. Instead, hospital leaders are increasingly cautious about their spending and the technology they test out, insisting that new products demonstrate concrete, measurable benefits to patients without disrupting an already fatigued clinical workforce — a marked difference from the pr

Hospitals 266

Hospitals 266

BioPharma Dive

NOVEMBER 20, 2023

Called Evinova, the unit will operate as a separate business within AstraZeneca, which sees digital health solutions as a market primed for growth.

113

113

STAT

NOVEMBER 20, 2023

LONDON — The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. The plan, which goes into effect next year, was announced Monday in a joint statement from the government, England’s National Health Service, and the Association of the British Pharmaceutical Industry.

Drug Pricing 262

Drug Pricing 262

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

The Pharmacist

NOVEMBER 20, 2023

UK research has uncovered more rapid cognitive decline in the over-50s during the pandemic, highlighting the need for public health measures to protect against dementia risk. Covid-19 infection was found to be a risk factor but the general more rapid decline in brain health was apparent even if people had not had the virus, researchers […] The post Pandemic lockdowns led to sustained cognitive decline among older adults appeared first on The Pharmacist.

86

86

STAT

NOVEMBER 20, 2023

Good morning and welcome to Thanksgiving week! STAT reporter Andrew Joseph here filling in for Mr. Pharmalot today. It’s my first Thanksgiving since moving over to London to expand STAT’s European coverage, but never fear, a Thanksgiving feast will be had on Thursday. (A reminder: It’s not too early to get started on some prep. I made my pie crusts over the weekend and they will hang in the freezer for a few days.

209

209

BioPharma Dive

NOVEMBER 20, 2023

The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.

106

106

STAT

NOVEMBER 20, 2023

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

Drug Pricing 179

Drug Pricing Drug Development 179

Pharma Times

NOVEMBER 20, 2023

The OpenSAFELY platform will support the discovery of new treatments - News - PharmaTimes

133

133

pharmaphorum

NOVEMBER 20, 2023

The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in Germany next year.

98

98

Express Pharma

NOVEMBER 20, 2023

The Express Pharma – Nutrify Today Boardroom series offers a platform for meaningful dialogues on the vast ocean of opportunities for the Indian pharma sector to be reaped in nutraceuticals, provided the right course is set for long and sustainable growth. In a thought-provoking discussion, industry leaders from India, the US, and Japan, unravel the dynamics behind the creation of a $100 billion nutraceutical ecosystem in India.

98

98

Pharmaceutical Technology

NOVEMBER 20, 2023

Takhzyro has been approved for the routine prevention of recurrent hereditary angioedema attacks in patients aged 2 years and older.

111

111

Express Pharma

NOVEMBER 20, 2023

The Union Health Ministry has released the draft National Pharmacy Commission Bill, 2023, which seeks to repeal the Pharmacy Act of 1948 and replace the Pharmacy Council of India with a national commission. The ministry put up the draft bill on its website on November 14 seeking comments from the public. The proposed bill aims to provide for a pharmacy education system that improves access to quality and affordable pharmacy or pharmaceutical education, ensures availability of adequate and high-q

91

91

Pharmaceutical Technology

NOVEMBER 20, 2023

The value of haemophilia gene therapies like Roctavian and Hemgenix hinge on long-term efficacy and innovative payment structures play a key role.

98

98

Express Pharma

NOVEMBER 20, 2023

The Express Pharma – Nutrify Today Boardroom series offers a platform for meaningful dialogues on the vast ocean of opportunities for the Indian pharma sector to be reaped in nutraceuticals, provided the right course is set for long and sustainable growth. This engaging panel discussion gives deep insights from a conversation with KoLs representing various specialties, as they share their take on responsible nutraceuticals.

Hospitals 90

Hospitals Diabetes 90

European Pharmaceutical Review

NOVEMBER 20, 2023

Eli Lilly and Company has announced that it plans to construct a new $2.5 billion parenteral (injectable) manufacturing site in Alzey, Rhineland-Palatinate, Germany. Supporting European parenteral manufacture and supply Alongside expanding the company’s global parenteral product and device manufacturing network, the new facility will support the higher demand for Eli Lilly’s medicines, including its diabetes and obesity portfolio.

Diabetes 85

Diabetes 85

Pharmaceutical Technology

NOVEMBER 20, 2023

AstraZeneca has launched a new digital health solutions business, Evinova, to expedite innovation in the life sciences industry.

100

100

Express Pharma

NOVEMBER 20, 2023

CStone Pharmaceuticals’ sugemalimab (Cejemly) has been approved by the China National Medical Products Administration (NMPA) for the treatment of relapsed or refractory extranodal natural killer/T-cell lymphoma (r/r ENKTL) in October 2023. With this approval, sugemalimab becomes the first anti-PD-1/PD-L1 monoclonal antibody approved for r/r ENKTL globally and is expected to boost CStone’s presence in the oncology market in China, says GlobalData.

Chemotherapy 83

Chemotherapy 83

BioPharma Dive

NOVEMBER 20, 2023

Biopharma companies capture data across a variety of different fronts and, so this data must be managed effectively in order to unlock business efficiencies and drive improvements.

77

77

European Pharmaceutical Review

NOVEMBER 20, 2023

On World Antibiotic Awareness Week (WAAW), 18-24 November 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the importance of efficient legislation for determining the EU’s future actions in the challenge to overcome antimicrobial resistance (AMR). The trade association for Europe’s pharmaceutical industry urged in a statement that in facing the threat of AMR, a “comprehensive approach, encompassing enhanced surveillance, prudent use, preventive

Vaccines 77

Vaccines 77

The Pharmacist

NOVEMBER 20, 2023

Antimicrobial supply will be ‘closely monitored’ following the launch of Pharmacy First, with an evaluation of the service’s impact on antimicrobial resistance to be commissioned by the National Institute for Health and Care Research (NIHR). In a letter outlining the service, the Department of Health and Social Care (DHSC), NHS England (NSHE) and the sector’s […] The post AMR to be ‘closely monitored’ after Pharmacy First launch appeared first on The Pharmacist.

65

65

World Pharma News

NOVEMBER 20, 2023

It has been uncertain how Mycobacterium tuberculosis deflects the immune response in humans, though evidence has pointed to host immunometabolism - the intrinsic link between metabolism in immune cells and their immune function. The pathogen M. tuberculosis is known to disrupt a metabolic pathway called glycolysis in infected myeloid cells, which include macrophages, through an unclear mechanism.

Immunity 73

Immunity Immunization 73

BioPharma Dive

NOVEMBER 20, 2023

Company shares fell by one-fifth after study monitors called for halting a planned 18,000-person trial because Bayer’s experimental drug wasn’t working as well as Eliquis.

65

65

Pharmaceutical Business Review

NOVEMBER 20, 2023

EBGLYSS is intended for patients aged 12 years and above who are candidates for systemic therapy. The company plans to begin selling the product in Germany initially and will gradually introduce it in additional European countries by the end of next year. Lebrikizumab is a monoclonal antibody, which binds IL-13 with high affinity for preventing the IL-13Rα1/IL-4Rα heterodimer complex formation and subsequent signalling, thereby suppressing the biological effects of IL-13.

64

64

Pharmafile

NOVEMBER 20, 2023

Astellas Pharma and Propella Therapeutics have announced that Astellas and Propella have entered a merger agreement in which Astellas will acquire Propella for approximately $175m. Through this acquisition, Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor in development by Propella for the treatment of prostate cancer.

63

63

pharmaphorum

NOVEMBER 20, 2023

Bayer pulls atrial fibrillation study for asundexian Phil.

108

108

Drug Patent Watch

NOVEMBER 20, 2023

Annual Drug Patent Expirations for PROMACTA+KIT Promacta Kit is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents… The post New patent expiration for Novartis drug PROMACTA KIT appeared first on DrugPatentWatch - Make Better Decisions.

59

59

pharmaphorum

NOVEMBER 20, 2023

NICE to consult on inflation-busting fee increases Mike.

109

109

Drug Patent Watch

NOVEMBER 20, 2023

Annual Drug Patent Expirations for PROMACTA Promacta is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. There are eight patents protecting… The post New patent expiration for Novartis drug PROMACTA appeared first on DrugPatentWatch - Make Better Decisions.

59

59